Cardiosense is pioneering a digital biomarker platform that utilizes innovative multi-sensor devices and proprietary algorithms to identify early indicators of cardiac disease and facilitate personalized treatment. Their approach involves mining raw biosignals to gain unprecedented insights into cardiac function, which is supported by over a decade of research. The company has developed an advanced signal processing pipeline designed to detect pre-symptomatic markers of cardiac conditions, emphasizing the importance of early intervention in patient care.

The company offers an end-to-end patient monitoring and sensor analytics ecosystem, featuring the CardioTag Sensor, a medical-grade wearable device that enables wireless monitoring of patients from hospital settings to their homes. Additionally, the Wavesense Platform serves as a device-agnostic software solution that aggregates, transmits, and analyzes physiological sensor data. Cardiosense also employs clinical AI to create digital biomarkers for early disease detection, leveraging deep learning techniques applied to raw physiological waveforms, thereby enhancing the accuracy and effectiveness of cardiac care.

United States

Contact: contact@cardiosense.com

Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy. 


Cardiosense

Company Details